Immunocore Holdings plc
IMCRNext catalyst
IMC-R117C
Cancer
Get an email about IMCR's next catalysts
Track Immunocore Holdings (IMCR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
4 upcoming, 2 past
IMC-R117C Phase 2 Est. Readout
Primary completion for IMC-R117C trial (NCT06840119) in Cancer
SourceTebentafusp Phase 2 Est. Readout (TebeMRD)
Estimated primary completion for Tebentafusp trial (NCT05315258) in Melanoma (Skin). Topline data typically follows completion by weeks to months.
SourceTebentafusp-Tebn Phase 2 Est. Readout
Estimated primary completion for Tebentafusp-Tebn trial (NCT06414590) in Locally Advanced Unresectable Uveal Melanoma. Topline data typically follows completion by weeks to months.
SourceBrenetafusp Phase 3 Est. Readout (PRISM-MEL-301)
Primary completion for Brenetafusp trial (NCT06112314) in Advanced Melanoma
SourceMarket Overview
Stock performance and key metrics
Brenetafusp
Select Advanced Solid Tumors
Tebentafusp
Advanced Melanoma
Tebentafusp with Pembrolizumab
Advanced Melanoma
IMCgp100
Uveal Melanoma
Tebentafusp-Tebn
Locally Advanced Unresectable Uveal Melanoma
Brenetafusp and chemotherapy
Select Advanced Solid Tumors
Brenetafusp and tebentafusp
Select Advanced Solid Tumors
Brenetafusp and kinase inhibitors
Select Advanced Solid Tumors
Antiangiogenic Agent
Cancer
Kinase inhibitor
Cancer
Monoclonal antibody
Cancer
Brenetafusp and pembrolizumab
Select Advanced Solid Tumors
Brenetafusp and monoclonal antibodies and chemotherapy
Select Advanced Solid Tumors
IMC-R117C
Cancer
Brenetafusp and bevacizumab
Select Advanced Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brenetafusp | Phase 3 | Select Advanced Solid Tumors | - | - |
Tebentafusp | Phase 3 | Advanced Melanoma | - | - |
Tebentafusp with Pembrolizumab | Phase 3 | Advanced Melanoma | - | - |
IMCgp100 | Phase 2 | Uveal Melanoma | - | - |
Tebentafusp-Tebn | Phase 2 | Locally Advanced Unresectable Uveal Melanoma | - | - |
Brenetafusp and chemotherapy | Phase 2 | Select Advanced Solid Tumors | - | - |
Brenetafusp and tebentafusp | Phase 2 | Select Advanced Solid Tumors | - | - |
Brenetafusp and kinase inhibitors | Phase 2 | Select Advanced Solid Tumors | - | - |
Antiangiogenic Agent | Phase 2 | Cancer | - | - |
Kinase inhibitor | Phase 2 | Cancer | - | - |
Monoclonal antibody | Phase 2 | Cancer | - | - |
Brenetafusp and pembrolizumab | Phase 2 | Select Advanced Solid Tumors | - | - |
Brenetafusp and monoclonal antibodies and chemotherapy | Phase 2 | Select Advanced Solid Tumors | - | - |
IMC-R117C | Phase 2 | Cancer | - | - |
Brenetafusp and bevacizumab | Phase 2 | Select Advanced Solid Tumors | - | - |
Frequently asked questions
What is in Immunocore Holdings plc's drug pipeline?→
CatalystAlert tracks 15 drug candidates in Immunocore Holdings plc's (IMCR) pipeline across Phase 3, Phase 2. Its lead program is Brenetafusp (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immunocore Holdings plc's next FDA catalyst?→
Immunocore Holdings plc's (IMCR) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMCR biotech catalysts?→
Add IMCR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immunocore Holdings plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.